Drugs to Watch 2026: Reshaping oncology therapeutic strategy through targeted protein degradation
Speakers
Drug developers are increasingly turning to targeted protein degradation (TPD) to address oncology targets long considered “undruggable.” By leveraging the cell’s intrinsic protein disposal machinery, TPD therapies aim to selectively eliminate disease‑driving proteins at their source—offering a fundamentally different approach from traditional small‑molecule inhibition.
As innovation accelerates, a growing pipeline of TPD agents is emerging across hematologic and solid tumors, with several programs generating meaningful clinical and commercial interest.
In this on‑demand webinar, Clarivate analysts examine how TPD is reshaping the oncology drug development landscape, using insights from two Drugs to Watch as representative case studies:
- BGB‑16673 – a chimeric degradation activation compound (CDAC) targeting BTK, under development for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
- Mezigdomide – a CELMoD therapy being developed for relapsed or refractory multiple myeloma
Through these examples, the session assesses how next‑generation protein degraders may differentiate from established therapies and what factors will influence their long‑term clinical and commercial success.
